- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
HyperBranch licenses ocular bandage to BD
HyperBranch Medical Technology Inc. has granted BD Medical-Ophthalmic Systems, a unit of Becton, Dickinson and Co., an exclusive worldwide license to market its liquid ocular bandage (OcuSeal), according to a prepared statement.
Durham, NC
-HyperBranch Medical Technology Inc. has granted BD Medical-Ophthalmic Systems, a unit of Becton, Dickinson and Co., an exclusive worldwide license to market its liquid ocular bandage (OcuSeal), according to a prepared statement.
The synthetic hydrogel bandage is designed to be used as a temporary protective barrier for postsurgical, posttraumatic, and nontraumatic ocular conditions. It has been engineered to form a low-profile, smooth, soft, and transparent protective barrier film on the ocular surface and decrease surgery time, reduce the need for sutures, and reduce the complications typically associated with surgical incisions, such as infection and patient discomfort, the company said.
